Basic Responsive HTML5
  • About
    • Corporate Overview
    • Founders
    • Management
    • Scientific Advisory Board
    • Board of Directors
    • Board of Advisors
    • Partnerships
  • Videos
    • ACP Testimonials
    • CEO Updates
    • News
  • Technology
    • Technology Overview
    • Manufacturing
    • Intellectual Property
    • Publications
  • Clinical Pipeline
    • ACP-01 Phase II Clinical Trial for CLI
    • CLI Phase II Trial Summary
    • Platform
    • Critical Limb Ischemia
  • Investors
    • Investor Overview
    • Analysts
    • A Three Minute Summary
    • Public Filings
    • AGM Materials
  • News & Media
    • News / Press Releases
  • Contact
MENU ≡
  • About
    • Corporate Overview
    • Founders
    • Management
    • Scientific Advisory Board
    • Board of Directors
    • Board of Advisors
    • Partnerships
  • Videos
    • ACP Testimonials
    • CEO Updates
    • News
  • Technology
    • Technology Overview
    • Manufacturing
    • Intellectual Property
    • Publications
  • Clinical Pipeline
    • ACP-01 Phase II Clinical Trial for CLI
    • CLI Phase II Trial Summary
    • Platform
    • Critical Limb Ischemia
  • Investors
    • Investor Overview
    • Analysts
    • A Three Minute Summary
    • Public Filings
    • AGM Materials
  • News & Media
    • News / Press Releases
  • Contact

News & Media

  • all
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014

Feb 11 / 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
Jan 28 / 2021

HEMOSTEMIX ANNOUNCES HS 12 – 01 CLINICAL TRIAL COMPLETION OF SUBJECTS’ FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED
Jan 22 / 2021

HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
Jan 04 / 2021

HEMOSTEMIX ANNOUNCES GRANT OF STOCK OPTIONS

  • Contact
  • Safe Harbour

Copyright © 2021 Hemostemix Inc. All rights reserved.